Skip to content

Insider · CIK 0002013809

Tuan Tu Diep

officer

Files at SKYE (Skye Bioscience, Inc.). First filing Nov 20, 2024, latest Nov 20, 2024.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $98k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

SKYE: Skye Bioscience, Inc.

SKYEOct 9, 2026 · close 1.69

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
45Moderate
SKYEsell 4
Skye Bioscience, Inc.
$98k
19,574 shares
-19%-

Planned sales

Form 144 notices this insider filed before selling restricted or control stock, newest first.

FiledCompanySharesValueSale datePast 3 months
Nov 15, 2024 SKYE
Skye Bioscience, Inc.
22,877
0.08% of outstanding
$126kNov 15, 2024none

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Feb 6, 2026SKYE
Skye Bioscience, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+125,000$0.00$0125,000Feb 9, 2026
Feb 24, 2025SKYE
Skye Bioscience, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+150,000$0.00$0150,000Feb 26, 2025
Nov 15, 2024SKYE
Skye Bioscience, Inc.
SOpen-market sale
Common Stock
-85$5.55$472101,748Nov 20, 2024
Nov 18, 2024SKYE
Skye Bioscience, Inc.
SOpen-market sale
Common Stock
-19,489$4.99$97k82,259Nov 20, 2024
Oct 28, 2024SKYE
Skye Bioscience, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+125,000$0.00$0125,000Oct 30, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Tuan Tu Diep: insider trades and track record | InsiderTell